Logo

Pfizer Reports Updated Results of Paxlovid (nirmatrelvir and ritonavir) in the P-II/III (EPIC-SR) Trial for the Treatment of COVID-19

Share this
Pfizer Reports Updated Results of Paxlovid (nirmatrelvir and ritonavir) in the P-II/III (EPIC-SR) Trial for the Treatment of COVID-19

Pfizer Reports Updated Results of Paxlovid (nirmatrelvir and ritonavir) in the P-II/III (EPIC-SR) Trial for the Treatment of COVID-19

Shots:

  • The P-II/III (EPIC-SR) trial evaluated Paxlovid (BID for 5 days) vs PBO in a ratio (1:1) in 1153 patients who are at standard risk for developing sev. COVID-19
  • The updated analysis showed a non-significant 51% relative risk reduction; 57% in hospitalization or death in a sub-group analysis of vaccinated patients. In an additional analysis of 2EPs, 62% reduction in COVID-19-related medical visits/day
  • In pre-specified analysis, 72% reduction on avg. no. of days in hospital & the results were consistent with (EPIC-HR1) study, discontinuation due to AEs (1.7% vs 1%). The company cease enrollment in the (EPIC-SR) trial due to the low rate of hospitalization or death & will continue to access treatment in patients with high unmet need

Ref: Pfizer| Image: Pfizer

Click here to­ read the full press release 

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions